I. Shapira

发表

Ethical aspects of participation in the Database of Genotypes and Phenotypes of the National Center for Biotechnology Information

M. Bertagnolli, P. Friedman, L. Dressler, 2012, Cancer.

SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in Peripheral Blood of Patients with Sickle Cell Disease

J. Simon, I. Shapira, Tracian James-Goulbourne, 2016 .

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

H. Wildiers, M. Aapro, C. Steer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin‐based oxygen carrier: a case report and review of literature

J. Kolitz, I. Shapira, A. Shander, 2010, Transfusion.

Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer

Annette Lee, P. Gregersen, A. Liew, 2017, Journal of Investigative Medicine.

Privacy Concerns About Personal Health Information and Fear of Unintended Use of Biospecimens Impact Donations by African American Patients

I. Shapira, Abhimanyu Amarnani, L. Martello, 2019, Journal of Cancer Education.

Evolving lipid-based delivery systems in the management of neoplastic disease

R. Gralla, I. Shapira, D. Budman, 2011 .

Heparin-Induced Thrombocytopenia Complicating Hemodialysis

I. Shapira, D. Budman, T. Bradley, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer

M. Ellis, L. Carey, H. Rugo, 2017 .

Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial

R. Gralla, I. Shapira, D. Budman, 2012, Supportive Care in Cancer.

M. Ellis, E. Winer, C. Hudis, 2015, Breast Cancer Research and Treatment.

Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients

I. Shapira, A. Guddati, P. S. Joy, 2018, Journal of Cancer Research and Clinical Oncology.

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

E. Winer, L. Carey, W. Barry, 2013 .

Early intervention results in lower mortality in patients with cancer hospitalized for metastatic spinal cord compression

G. Kumar, I. Shapira, A. Guddati, 2017, Journal of Investigative Medicine.

Need for Inferior Vena Cava Filters in Cancer Patients: A Surrogate Marker for Poor Outcome

I. Shapira, D. Budman, T. Bradley, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Prognosis of lymphoma in patients following treatment with 6‐mercaptopurine/azathioprine for inflammatory bowel disease

I. Shapira, D. Present, B. Korelitz, 2012, Inflammatory bowel diseases.

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.

J. Salmon, I. Shapira, S. Allen, 2012, Arthritis and rheumatism.

Emerging role of small ribonucleic acids in gastrointestinal tumors.

I. Shapira, D. Budman, B. Mehrotra, 2010, Critical reviews in oncology/hematology.

Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.

R. Schilsky, M. Bertagnolli, P. Friedman, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes

Annette Lee, P. Gregersen, H. Khalili, 2013, British Journal of Cancer.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

M. Ellis, E. Winer, C. Hudis, 2015, The New England journal of medicine.

Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge

I. Shapira, Christopher A. J. Roman, A. Naboush, 2017, Journal of Investigative Medicine.

Evolving Concepts: Immunity in Oncology from Targets to Treatments

I. Shapira, R. Gucalp, H. Khan, 2015, Journal of oncology.

Fighting colorectal cancer: molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians.

Z. Halpern, H. Hibshoosh, N. Arber, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Activation of c-K-ras mutations in human gastrointestinal tumors.

Z. Halpern, H. Hibshoosh, I. Shapira, 2000, Gastroenterology.

Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel.

A. Neugut, H. Hibshoosh, I. Weinstein, 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity

I. Shapira, Christopher A. J. Roman, S. Gottesman, 2006, Nature Immunology.

Heterogeneity of Breast Cancer Clinical Characteristics and Outcome in US Black Women—Effect of Place of Birth

E. Taioli, M. Camacho-Rivera, I. Shapira, 2014, The breast journal.

Evolving Concepts: How Diet and the Intestinal Microbiome Act as Modulators of Breast Malignancy

Annette Lee, E. Taioli, I. Shapira, 2013, ISRN oncology.

A critical analysis of prognostic factors in North American patients with human T‐cell lymphotropic virus type‐1‐associated adult T‐cell leukemia/lymphoma

V. Seshan, G. Bhagat, S. Horwitz, 2010, Cancer.

Implications of applied research for prognosis and therapy of breast cancer.

I. Shapira, D. Budman, T. Bradley, 2008, Critical reviews in oncology/hematology.

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

M. Ellis, C. Hudis, L. Carey, 2023, The New England journal of medicine.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.

Annette Lee, I. Shapira, D. Budman, 2013, Critical reviews in oncology/hematology.

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Lauren L. Ritterhouse, E. Winer, C. Hudis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives

I. Shapira, B. Baseri, Bachar Samra, 2018, Journal of Investigative Medicine.

Inflammatory Bowel Disease and Lymphoma: A Comprehensive Review for the General Gastroenterologist INFLAMMATORY BOWEL DISEASE: A PRACTICAL APPROACH, SERIES #76

I. Shapira, S. Katz, K. Sultan, 2012 .

Inflammatory Bowel Disease and Lymphoma : A Comprehensive Review for the General Gastroenterologist INFLAMMATORY BOWEL DISEASE

I. Shapira, S. Katz, K. Sultan, 2012 .

CHOP chemotherapy is better than non-doxorubicin based therapy in patients with HTLV-1 adult T-cell leukemia-lymphoma (ATLL)

I. Shapira, W. Solomon, J. Feldman, 2005 .

Beliefs and attitudes towards participating in genetic research – a population based cross-sectional study

P. Gregersen, E. Taioli, I. Shapira, 2013, BMC Public Health.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

M. Ellis, E. Winer, C. Hudis, 2016, JAMA oncology.

Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).

M. Ellis, E. Winer, C. Hudis, 2017 .

Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP)

B. Louie, R. Hawtin, A. Cesano, 2014, Journal of Translational Medicine.

Analysis of nationwide trends and outcomes of percutaneous endoscopic gastrostomy (PEG) tube placement in hospitalized patients with cancer over a 13-year period

G. Kumar, I. Shapira, A. Guddati, 2017, Journal of Investigative Medicine.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.

M. Ellis, C. Hudis, L. Carey, 2023, The Lancet. Oncology.